13 active not recruiting. 13 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 13 |
| Phase 1 | 3 | Active not recruiting 3 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
| Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Atezolizumab, BEGEV - Relapsed or Refractory Hodgkin's Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 122 | 2023-02-27 | 2026-09-11 |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Bendamustine, Rituximab, Tazemetostat - Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Vaishalee Kenkre | 42 | 2023-01-26 | 2026-02-17 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia Acalabrutinib, Bendamustine, Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Active not recruiting | Sunnybrook Health Sciences Centre | 63 | 2021-03-02 | 2026-09-03 |
| Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) CD30.CAR-T, Fludarabine, Bendamustine - Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent | Phase 2 | Active not recruiting | Tessa Therapeutics | 97 | 2021-02-01 | 2023-04-05 |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Zanubrutinib - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | German CLL Study Group | 42 | 2020-10-01 | 2026-08-20 |
| A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Acalabrutinib, Bendamustine, Bendamustine Hydrochloride - Liver Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 360 | 2019-12-13 | 2026-09-14 |
| Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Bendamustine, Obinutuzumab, Venetoclax - CCND1 Positive, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Emory University | 23 | 2019-04-11 | 2026-10-02 |
| Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 bendamustine, Etoposide, Doxorubicin - Hodgkin Lymphoma | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 232 | 2018-12-12 | 2026-06-17 |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma Rituximab, Bendamustine, Cytarabine - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Christine Ryan | 23 | 2012-08-16 | 2026-06-08 |
| Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma rituximab, Bendamustine, bortezomib - Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Eastern Cooperative Oncology Group | 373 | 2012-08-09 | 2026-06-03 |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Pentostatin, Rituximab, Bendamustine - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 69 | 2010-07-01 | 2026-10-15 |
Lymphoma, Mantle-Cell (4) · Hodgkin Disease (3) · Lymphoma (2) · Lymphoma, Follicular (2) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, B-Cell (1) · Leukemia, Hairy Cell (1) · Neoplasm, Residual (1) · Neoplasms (1) · Proteostasis Deficiencies (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Celgene (1) · Christine Ryan (1) · Columbia University (1) · ECOG-ACRIN Cancer Research Group (1) · Eastern Cooperative Oncology Group (1) · Emory University (1) · Fondazione Italiana Linfomi - ETS (1) · German CLL Study Group (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1) · Sunnybrook Health Sciences Centre (1) · Tessa Therapeutics (1) · Vaishalee Kenkre (1)
United States (10) · Canada (3) · Germany (2) · Italy (2) · Australia (1) · Brazil (1) · Chile (1) · France (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Armando Santoro, MD (1) · Christine Ryan, MD (1) · Helen Heslop, MD (1) · Jonathon B. Cohen, MD, MS (1) · Matthew Ehrhardt, MD, MS (1) · Mitchell R. Smith, MD, PhD (1) · Neil L Berinstein, MD (1) · Nina D Wagner-Johnston (1) · Paula Cramer, Dr. med. (1) · Rajshekhar Chakraborty, MD (1) · Robert J Kreitman, M.D. (1) · Vaishalee Kenkre, MD (1)
PMID 26729345, PMID 32126141, PMID 37183115, PMID 38820500, PMID 39883943, PMID 40226119, PMID 41060318
2018 (1), P30CA138292 (1), U10CA180820 (1)